CorMedix (CRMD) Expected to Announce Earnings on Thursday

CorMedix (NASDAQ:CRMD) is expected to release its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of $0.86 per share and revenue of $127.0190 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

CorMedix Stock Down 4.2%

Shares of NASDAQ CRMD opened at $6.91 on Wednesday. The company has a current ratio of 1.94, a quick ratio of 1.73 and a debt-to-equity ratio of 0.39. CorMedix has a 12-month low of $5.60 and a 12-month high of $17.43. The firm’s 50-day moving average price is $8.39 and its 200-day moving average price is $10.45. The stock has a market capitalization of $544.44 million, a price-to-earnings ratio of 3.35 and a beta of 1.31.

CorMedix declared that its Board of Directors has approved a share buyback program on Monday, February 2nd that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 12.3% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other CorMedix news, Director Steven W. Lefkowitz sold 40,000 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $11.88, for a total transaction of $475,200.00. Following the transaction, the director directly owned 80,498 shares in the company, valued at $956,316.24. This trade represents a 33.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Alan W. Dunton sold 20,000 shares of the stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $13.00, for a total value of $260,000.00. Following the transaction, the director directly owned 40,250 shares in the company, valued at $523,250. The trade was a 33.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 90,000 shares of company stock valued at $1,095,200 over the last quarter. 3.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CorMedix

A number of hedge funds have recently made changes to their positions in CRMD. Marshall Wace LLP boosted its position in shares of CorMedix by 34.6% in the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock worth $40,397,000 after purchasing an additional 893,518 shares in the last quarter. Deerfield Management Company L.P. acquired a new position in CorMedix during the 3rd quarter valued at about $38,656,000. State Street Corp raised its stake in CorMedix by 4.6% in the fourth quarter. State Street Corp now owns 1,920,861 shares of the company’s stock valued at $22,340,000 after buying an additional 85,240 shares during the last quarter. Geode Capital Management LLC boosted its holdings in CorMedix by 5.7% in the fourth quarter. Geode Capital Management LLC now owns 1,912,233 shares of the company’s stock worth $22,243,000 after acquiring an additional 102,461 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its holdings in CorMedix by 68.4% in the third quarter. Alyeska Investment Group L.P. now owns 1,262,979 shares of the company’s stock worth $14,688,000 after acquiring an additional 512,979 shares in the last quarter. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CRMD. Weiss Ratings restated a “hold (c)” rating on shares of CorMedix in a research report on Wednesday, January 21st. Wall Street Zen downgraded shares of CorMedix from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Zacks Research cut shares of CorMedix from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 10th. HC Wainwright cut their price target on shares of CorMedix from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Finally, Truist Financial set a $16.00 price objective on shares of CorMedix in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, CorMedix has an average rating of “Moderate Buy” and an average price target of $15.86.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.